Covid-19: Effects of Azithromycin/Hydroxychloroquine/Ivermectin in ambulatory and hospitalized patients

Henry Mejia-Zambrano; Livia Ramos-Calsin

doi:10.54034/mic.e1231

Authors

Henry Mejia-Zambrano San Juan Bautista Private University. Lima, Peru
Livia Ramos-Calsin San Juan Bautista Private University. Lima, Peru

DOI:

https://doi.org/10.54034/mic.e1231

Keywords:

COVID-19, SARS-CoV-2, azithromycin, hydroxychloroquine, ivermectin

Abstract

Introducción: A finales de 2019, surgió el brote de un nuevo coronavirus que desencadenó el síndrome respiratorio agudo severo coronavirus 2 (SARS-CoV-2), originado en la provincia de Hubei, ciudad de Wuhan, República Popular de China, provocando una pandemia global y una amenaza para la salud pública. Objetivo : Esta revisión sistemática tiene como objetivo determinar los efectos de la azitromicina, hidroxicloroquina e ivermectina en pacientes ambulatorios y hospitalizados con covid-19. Métodos: Realizamos una búsqueda bibliográfica en Pub Med / MEDLINE hasta el 4 de junio de 2021, las estrategias de búsqueda se evaluaron utilizando el programa Manual Cochrane de revisiones sistemáticas. Se utilizó el programa Mendeley para gestionar las referencias bibliográficas. Resultados:En la búsqueda inicial se registraron 832 estudios, de los cuales se incluyeron 17 publicaciones. Además, incluimos un artículo secundario de la búsqueda adicional de los 17 artículos. La azitromicina y / o hidroxicloroquina aumentan la mortalidad y provocan eventos adversos en comparación con los grupos de atención habitual (27% vs 25%, OR = 0,98, IC 95% = 0,58-1,74, p = 1,00) e ivermectina con respecto al grupo control en la resolución de síntomas (82% vs 79%) y eventos adversos (52% vs 56%), de varios estudios. Conclusiones: la calidad de la evidencia sobre la efectividad y ventajas de la azitromicina, hidroxicloroquina e ivermectina en el tratamiento del COVID-19 en pacientes ambulatorios y hospitalizados es baja.

References

Dhama K, Khan S, Tiwari R, Sircar Sh, Bhat S, Malik YS et al. Coronavirus disease 2019–COVID-19. Clin Microbiol Rev. 2020; 33(4): 1-48. Doi: 10.1128/CMR.00028-20

Gralinski LE, Menachery VD. Return of the coronavirus: 2019-nCoV. Viruses. 2020; 12(2): 135. Doi: 10.3390/v12020135.

Sharma A, Tiwari S, Deb M, Marty JL. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. Int J Antimicrob Agents. 2020; 56(2): 106054. Doi: 10.1016/j.ijantimicag.2020.106054.

Bakadia BM., He F, Souho T, Lamboni L, Ullah MW, Boni BO et al. Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine. Biomed Pharmacother. 2021; 133: 111008. Doi: 10.1016/j.biopha.2020.111008.

Caly L., Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020; 178: 104787. Doi: 10.1016/j.antiviral.2020.104787.

Perricone C, Triggianese P, Bartoloni E, Cafaro G, Bonifacio AF, Bursi R et al. The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. J Autoimmun. 2020; 111: 102468. Doi: 10.1016/j.jaut.2020.102468.

Andreani J, Le Bideau M, Duflot I, Jardot P, Rolland C, Boxberger M, et al. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. Microb Pathog. 2020; 145: 104228. Doi: 10.1016/j.micpath.2020.104228.

Liang C, Tian L, Liu Y, Hui N, Qiao G, Li H, et al. A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir. Eur J Med Chem. 2020; 201: 112527. Doi: 10.1016/j.ejmech.2020.112527.

Kaptein SJF, Jacobs S, Langendries L, Seldeslachts L, Ter Horst S, Liesenborghs L, et al. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity. Proc Natl Acad Sci USA. 2020; 117(43): 26955-26965. Doi: 10.1073/pnas.2014441117.

Urrutia G, Bonfill X. PRISMA statement: a proposal to improve the publication of systematic reviews and meta-analyzes. Clinical Medicine. 2010; 135 (11): 507-511. https://es.cochrane.org/sites/es.cochrane.org/files/public/uploads/PRISMA_Spanish.pdf

The GRADE system: a change in the way of evaluating the quality of evidence and the strength of recommendations. https://scielo.conicyt.cl/pdf/rmc/v142n5/art12.pdf

Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga V, Avezumet A, et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. N Engl J Med. 2020; 383(21): 2041-2052. Doi: 10.1056/nejmoa2019014.

Furtado RHM, Berwanger O, Fonseca HA, Corrêa TD, Ferraz LR, Lapa MG, et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet. 2020; 396(10256): 959-967. Doi: 10.1016/S0140-6736(20)31862-6.

Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020; 56(1): 106239. Doi: 10.1016/j.ijantimicag.2020.105949.

Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med. 2020; 383(6): 517-525. Doi: 10.1056/nejmoa2016638.

Mitjà O, Corbacho-Monné M, Ubals M, Alemany A, Suñer C, Tebé C, et al. A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19. N Engl J Med. 2021; 384(5): 417-427. Doi: 10.1056/nejmoa2021801.

Horby P, Mafhan M, Linsell L, Bell JL, Staplin N, Emberson JR, et al. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 383(21): 2030-2040. Doi: 10.1056/nejmoa2022926.

Self W, Semler M, Leither LM, Casey JD, Angus DC, Browe RG, et al. Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients with COVID-19: A Randomized Clinical Trial. JAMA. 2020; 324(21): 2165-2176. Doi: 10.1001/jama.2020.22240.

Abella B, Jolkovsky E, Biney BT, Uspal JE, Hyman M, Frank I, et al. Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis among Health Care Workers: A Randomized Clinical Trial. JAMA Intern Med. 2020; 181(2): 195-202. Doi: 10.1001/jamainternmed.2020.6319.

Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: Open label, randomised controlled trial. BMJ. 2020; 369: 1849. Doi: 10.1136/bmj.m1849.

Abd-Elsalam S, Esmail E, Khalaf M, Abdo EF, Medhat MA, El Ghafar MSA, et al. Hydroxychloroquine in the treatment of COVID-19: A multicenter randomized controlled study. Am J Trop Med Hyg. 2020; 103(3): 1635-1639. Doi: 10.4269/ajtmh.20-0873.

Skipper C, Pastick K, Engen NW, Bangdiwala AS, Abassi M, Lofgren SM, et al. Hydroxychloroquine in Nonhospitalized Adults with Early COVID-19: A Randomized Trial. Ann Intern Med. 2020; 173(8): 623-631. Doi: 10.7326/M20-4207.

Sekhavati E, Jafari F, SeyedAlinaghi SA, Jamalimoghadamsiahkali S, Sadr S, Tabarestani M, et al. Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial. Int J Antimicrob Agents. 2020; 56(4): 106143. Doi: 10.1016/j.ijantimicag.2020.106143.

Shouman W. Prophylactic Ivermectin in COVID-19. Egipto. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04422561 (accessed Jun 10, 2020)

Lopez-Medina E, Lopez P, Hurtado IC, Dávalos DM, Ramirez O, Martínez E, et al. Effect of Ivermectin on Time to Resolution of Symptoms among Adults with Mild COVID-19: A Randomized Clinical Trial. JAMA. 2021. Doi: 10.1001/jama.2021.3071.

Rajter J, Sherman M, Fatteh N, Vogel F, Sacks J, Rajter JJ. Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study. Chest. 2021; 159(1): 85-92: Doi: 10.1016/j.chest.2020.10.009.

Rahman MA, Iqbal SA, Islam MA, Niaz MK, Hussain T, Siddiquee TH. Comparison of viral clearance between ivermectin with doxycycline and hydroxychloroquine with azithromycin in COVID-19 patients. J Bangladesh Coll Physicians Surg. 2020. Doi: 10.3329/jbcps.v38i0.47514.

Mahmud R, Alam I, Ahmed K, Kabir H, Sayeed S, Rassel M, et al. Clinical Trial of Ivermectin plus Doxycycline for the Treatmet of Confirmed Covid-19 Infection. ClinicalTrials.gov. https://www.cochranelibrary.com/es/central/doi/10.1002/central/CN-02163042/full (accessed Jun 9, 2020)